Table 1.
General characteristics of study population.
| Characteristics | Study population (n = 45) |
|---|---|
| Age, years, median (IQR) | 66 (56-71) |
| Sex (M/F), n | 27/18 |
| Duration of symptoms,days, median (IQR) | 3.7 (2.7-9.7) |
| Blood analyses, median (IQR) | |
| White Blood Cells, x106/L | 6740 (4920-8610) |
| Neutrophils, x106/L | 4670 (3460-7680) |
| Lymphocytes, x106/L | 820 (600-1210) |
| Monocytes, x106/L | 360 (240-510) |
| Platelets, x109/L | 194 (176-248) |
| Albumin, g/L | 3.6 (3.3-4.2) |
| D-Dimer, µg/L | 670.5 (389.5-2139) |
| Fibrinogen, mg/dL | 555 (398.3-575.5) |
| PaO2/FiO2 ratio | 309 (238.5-373.5) |
| Comorbidities, n (%) | |
| Smoke | 3 (6.6) |
| Diabetes mellitus | 7 (15.5) |
| Heart failure | 4 (8.8) |
| Vasculopathy | 10 (22.2) |
| Cerebrovascular events | 4 (8.8) |
| Asthma | 0 (0) |
| Chronic Obstructive Pulmonary Disease | 4 (8.8) |
| AIDS | 0 (0) |
| Symptoms, n (%) | |
| Fever | 33 (73.3) |
| Cough | 14 (31.1) |
| Dispnoea | 20 (44.4) |
| Diarrhea | 4 (8.8) |
| Headache | 2 (4.4) |
| Fatigue | 2 (4.4) |
| Therapy, n (%) | |
| Hydroxychloroquine | 33 (73.3) |
| Azithromycin | 19 (42.2) |
| Protease inhibitors | 7 (15.5) |
| Tocilizumab | 21 (46.6) |
| Steroids | 15 (33.3) |
| Enoxaparin | 24 (53.3) |
| Teicoplanin | 9 (20) |
| Outcomes, n (%) | |
| Intensive Care Unit admission | 21 (46.6) |
| Trombotic events | 6 (13.3) |
| Bloodstream infection | 9 (20) |
| Death | 10 (22.2) |
AIDS, Acquired Immune Deficiency Syndrome.